Moderately Active Ulcerative Colitis — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for moderately active ulcerative colitis. 4 active patents protecting 1 drugs from 0+ originators. First major cliff: 2027. Daily refresh.

1
Approved drugs
4
Active US patents
54/100
Avg vulnerability
—
Annual revenue covered

Originators in Moderately Active Ulcerative Colitis

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating moderately active ulcerative colitis. Each bar = one year. Y-axis scaled to peak year (2 patents).

1
27
2
28
1
30

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
MESALAMINE — 4 54 — 2027-07-24

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
8865688 MESALAMINE method of use 73 2030-05-01
8217083 MESALAMINE formulation 60 2028-06-06
8436051 MESALAMINE formulation 60 2028-06-06
7645801 MESALAMINE composition of matter 22 2027-07-24

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
7645801 MESALAMINE composition of matter 22 2027-07-24
8217083 MESALAMINE formulation 60 2028-06-06
8436051 MESALAMINE formulation 60 2028-06-06
8865688 MESALAMINE method of use 73 2030-05-01

Related